Tumor cyclooxygenase 2-dependent suppression of dendritic cell function

Sherven Sharma, Marina Stolina, Seok Chul Yang, Felicita Baratelli, Jeff F. Lin, Kimberly Calica Atianzar, Jie Luo, Li Zhu, Ying Lin, Min Huang, Mariam Dohadwala, Raj K. Batra, Steven M. Dubinett

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Dendritic cells (DCs) serve as professional antigenpresenting cells and are pivotal in the host immune response to tumor antigens. To define the pathways limiting DC function in the tumor microenvironment, we assessed the impact of tumor cyclooxygenase (COX)-2 expression on DC activities. Bone marrow-derived DCs were cultured in either tumor supernatant (TSN) or TSN from COX-2-inhibited tumors. After culture, DCs were pulsed with tumor-specific peptides, and their ability to generate antitumor immune responses was assessed following injection into established murine lung cancer. In vitro, DC phenotype, alloreactivity, antigen processing and presentation, and interleukin (IL)-10 and IL-12 secretion were evaluated. DCs cultured in TSN failed to generate antitumor immune responses and caused immunosuppressive effects that correlated with enhanced tumor growth. However, genetic or pharmacological inhibition of tumor COX-2 expression restored DC function and effective antitumor immune responses. Functional analyses indicated that TSN causes a decrement in DC capacity to (a) process and present antigens, (b) induce alloreactivity, and (c) secrete IL-12. Whereas TSN DCs showed a significant reduction in cell surface expression of CD11c, DEC-205, MHC class I antigen, MHC class II antigen, CD80, and CD86 as well as a reduction in the transporter-associated proteins, transporter associated with antigen processing 1 and 2, the changes in phenotype and function were not evident when DCs were cultured in supernatant from COX2-inhibited tumors. We conclude that inhibition of tumor COX-2 expression or activity can prevent tumor-induced suppression of DC activities.

Original languageEnglish (US)
Pages (from-to)961-968
Number of pages8
JournalClinical Cancer Research
Volume9
Issue number3
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Dendritic Cells
Neoplasms
Antigen Presentation
Interleukin-12
Phenotype
Histocompatibility Antigens Class I
Tumor Microenvironment
Histocompatibility Antigens Class II
Neoplasm Antigens
Immunosuppressive Agents
Interleukin-10
Lung Neoplasms
Bone Marrow
Pharmacology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sharma, S., Stolina, M., Yang, S. C., Baratelli, F., Lin, J. F., Atianzar, K. C., ... Dubinett, S. M. (2003). Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clinical Cancer Research, 9(3), 961-968.

Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. / Sharma, Sherven; Stolina, Marina; Yang, Seok Chul; Baratelli, Felicita; Lin, Jeff F.; Atianzar, Kimberly Calica; Luo, Jie; Zhu, Li; Lin, Ying; Huang, Min; Dohadwala, Mariam; Batra, Raj K.; Dubinett, Steven M.

In: Clinical Cancer Research, Vol. 9, No. 3, 01.03.2003, p. 961-968.

Research output: Contribution to journalArticle

Sharma, S, Stolina, M, Yang, SC, Baratelli, F, Lin, JF, Atianzar, KC, Luo, J, Zhu, L, Lin, Y, Huang, M, Dohadwala, M, Batra, RK & Dubinett, SM 2003, 'Tumor cyclooxygenase 2-dependent suppression of dendritic cell function', Clinical Cancer Research, vol. 9, no. 3, pp. 961-968.
Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar KC et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clinical Cancer Research. 2003 Mar 1;9(3):961-968.
Sharma, Sherven ; Stolina, Marina ; Yang, Seok Chul ; Baratelli, Felicita ; Lin, Jeff F. ; Atianzar, Kimberly Calica ; Luo, Jie ; Zhu, Li ; Lin, Ying ; Huang, Min ; Dohadwala, Mariam ; Batra, Raj K. ; Dubinett, Steven M. / Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 3. pp. 961-968.
@article{bc9ac4c6754145e09a53cbdb80c7c808,
title = "Tumor cyclooxygenase 2-dependent suppression of dendritic cell function",
abstract = "Dendritic cells (DCs) serve as professional antigenpresenting cells and are pivotal in the host immune response to tumor antigens. To define the pathways limiting DC function in the tumor microenvironment, we assessed the impact of tumor cyclooxygenase (COX)-2 expression on DC activities. Bone marrow-derived DCs were cultured in either tumor supernatant (TSN) or TSN from COX-2-inhibited tumors. After culture, DCs were pulsed with tumor-specific peptides, and their ability to generate antitumor immune responses was assessed following injection into established murine lung cancer. In vitro, DC phenotype, alloreactivity, antigen processing and presentation, and interleukin (IL)-10 and IL-12 secretion were evaluated. DCs cultured in TSN failed to generate antitumor immune responses and caused immunosuppressive effects that correlated with enhanced tumor growth. However, genetic or pharmacological inhibition of tumor COX-2 expression restored DC function and effective antitumor immune responses. Functional analyses indicated that TSN causes a decrement in DC capacity to (a) process and present antigens, (b) induce alloreactivity, and (c) secrete IL-12. Whereas TSN DCs showed a significant reduction in cell surface expression of CD11c, DEC-205, MHC class I antigen, MHC class II antigen, CD80, and CD86 as well as a reduction in the transporter-associated proteins, transporter associated with antigen processing 1 and 2, the changes in phenotype and function were not evident when DCs were cultured in supernatant from COX2-inhibited tumors. We conclude that inhibition of tumor COX-2 expression or activity can prevent tumor-induced suppression of DC activities.",
author = "Sherven Sharma and Marina Stolina and Yang, {Seok Chul} and Felicita Baratelli and Lin, {Jeff F.} and Atianzar, {Kimberly Calica} and Jie Luo and Li Zhu and Ying Lin and Min Huang and Mariam Dohadwala and Batra, {Raj K.} and Dubinett, {Steven M.}",
year = "2003",
month = "3",
day = "1",
language = "English (US)",
volume = "9",
pages = "961--968",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Tumor cyclooxygenase 2-dependent suppression of dendritic cell function

AU - Sharma, Sherven

AU - Stolina, Marina

AU - Yang, Seok Chul

AU - Baratelli, Felicita

AU - Lin, Jeff F.

AU - Atianzar, Kimberly Calica

AU - Luo, Jie

AU - Zhu, Li

AU - Lin, Ying

AU - Huang, Min

AU - Dohadwala, Mariam

AU - Batra, Raj K.

AU - Dubinett, Steven M.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Dendritic cells (DCs) serve as professional antigenpresenting cells and are pivotal in the host immune response to tumor antigens. To define the pathways limiting DC function in the tumor microenvironment, we assessed the impact of tumor cyclooxygenase (COX)-2 expression on DC activities. Bone marrow-derived DCs were cultured in either tumor supernatant (TSN) or TSN from COX-2-inhibited tumors. After culture, DCs were pulsed with tumor-specific peptides, and their ability to generate antitumor immune responses was assessed following injection into established murine lung cancer. In vitro, DC phenotype, alloreactivity, antigen processing and presentation, and interleukin (IL)-10 and IL-12 secretion were evaluated. DCs cultured in TSN failed to generate antitumor immune responses and caused immunosuppressive effects that correlated with enhanced tumor growth. However, genetic or pharmacological inhibition of tumor COX-2 expression restored DC function and effective antitumor immune responses. Functional analyses indicated that TSN causes a decrement in DC capacity to (a) process and present antigens, (b) induce alloreactivity, and (c) secrete IL-12. Whereas TSN DCs showed a significant reduction in cell surface expression of CD11c, DEC-205, MHC class I antigen, MHC class II antigen, CD80, and CD86 as well as a reduction in the transporter-associated proteins, transporter associated with antigen processing 1 and 2, the changes in phenotype and function were not evident when DCs were cultured in supernatant from COX2-inhibited tumors. We conclude that inhibition of tumor COX-2 expression or activity can prevent tumor-induced suppression of DC activities.

AB - Dendritic cells (DCs) serve as professional antigenpresenting cells and are pivotal in the host immune response to tumor antigens. To define the pathways limiting DC function in the tumor microenvironment, we assessed the impact of tumor cyclooxygenase (COX)-2 expression on DC activities. Bone marrow-derived DCs were cultured in either tumor supernatant (TSN) or TSN from COX-2-inhibited tumors. After culture, DCs were pulsed with tumor-specific peptides, and their ability to generate antitumor immune responses was assessed following injection into established murine lung cancer. In vitro, DC phenotype, alloreactivity, antigen processing and presentation, and interleukin (IL)-10 and IL-12 secretion were evaluated. DCs cultured in TSN failed to generate antitumor immune responses and caused immunosuppressive effects that correlated with enhanced tumor growth. However, genetic or pharmacological inhibition of tumor COX-2 expression restored DC function and effective antitumor immune responses. Functional analyses indicated that TSN causes a decrement in DC capacity to (a) process and present antigens, (b) induce alloreactivity, and (c) secrete IL-12. Whereas TSN DCs showed a significant reduction in cell surface expression of CD11c, DEC-205, MHC class I antigen, MHC class II antigen, CD80, and CD86 as well as a reduction in the transporter-associated proteins, transporter associated with antigen processing 1 and 2, the changes in phenotype and function were not evident when DCs were cultured in supernatant from COX2-inhibited tumors. We conclude that inhibition of tumor COX-2 expression or activity can prevent tumor-induced suppression of DC activities.

UR - http://www.scopus.com/inward/record.url?scp=0037343236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037343236&partnerID=8YFLogxK

M3 - Article

C2 - 12631593

AN - SCOPUS:0037343236

VL - 9

SP - 961

EP - 968

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -